In contrast to findings in AR+ TNBC [8], together these results suggest that 1 h pretreatment of apalutamide, or darolutamide, like enzalutamide, does not result in radiosensitisation of AR+/ER+ breast cancer cells in vitro. Here, ESR1 is linked to breast carcinoma.